Showing results (1-10 of 547) with videos related to

Sort By:
Pageof 55
European Journal of Cancer (Oxford, England : 1990)|June 9, 2006
Allogeneic haematopoietic cell transplantation for multiple myeloma: reducing transplant-related mortality while harnessing the graft-versus-myeloma effectRobert Zeiser, Jürgen Finke
Annals of Hematology|September 28, 2004
Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategiesRobert Zeiser, Reinhard Marks, Hartmut Bertz, et al.
Leukemia & Lymphoma|August 9, 2005
The death receptor pathway is not involved in alloreactive T-cell induced mitochondrial membrane permeabilityCarsten Grüllich, Suzanne McGoldrick, Robert Zeiser, et al.
Stem Cell Reviews|November 30, 2006
Stem cell plasticity: the debate begins to clarifyAlexandros Spyridonidis, Robert Zeiser, Marie Follo, et al.
Clinical Transplantation|May 10, 2005
Capillary electrophoresis for chimerism monitoring by PCR amplification of microsatellite markers after allogeneic hematopoietic cell transplantationAlexandros Spyridonidis, Robert Zeiser, Ralph Wäsch, et al.
Bone Marrow Transplantation|June 29, 2022
Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tractFrancesca Biavasco, Gabriele Ihorst, Ralph Wäsch, et al.
Bone Marrow Transplantation|November 20, 2024
Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxisThomas Meyer, Kristina Maas-Bauer, Ralph Wäsch, et al.
Clinical Transplantation|July 13, 2005
Fatal varicella zoster virus encephalitis in two patients following allogeneic hematopoietic stem cell transplantationBjörn Hackanson, Robert Zeiser, Thorsten A Bley, et al.
BMC Cancer|November 21, 2018
Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, et al.
Annals of Hematology|March 23, 2021
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCTHenning Schäfer, Jacqueline Blümel-Lehmann, Gabriele Ihorst, et al.
Pageof 55